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Abstract  
Introduction: infantile hemangioma is the most common benign tumor in infancy. Currently, oral propranolol is the treatment of choice for 
infantile hemangioma, but there is no consensus when it comes to its recommended dosage for this condition. Hence this study was conducted to 
find out the appropriate dosage of oral propranolol for treatment of infantile hemangioma. Methods: A prospective study was conducted on 25 
patients with infantile hemangioma, who were treated with gradually increasing dose of propranolol starting from a lower dose of 1mg/kg/day. 
Results: 17/22(76%) patients showed regression of the tumor at the dose of 1- 1.5 mg/kg/d. 5/22(24%) patients were unresponsive to the 
treatment with the lower dose and they did not respond even with the gradually escalated dose of 3-4 mg/kg/day. Conclusion: Propranolol in a 
lower dose of 1-1.5 mg/kg/day is safe and efficacious in the treatment of infantile hemangioma and the lesions which do not show initial response 
to the lower dose are unlikely to respond to the higher dose of 3-4 mg/kg/day. 
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Introduction 
 
Infantile hemangiomas are the most common infantile tumor [1, 2]. 
The prevalence of Infantile hemangioma in mature neonates is 
around 4.5% with a female (2.3-2.9 times higher) and white 
predominance [3]. The predominant locations are head and neck 
[4]. They arise in initial few weeks of life and then display a period 
of active growth followed by spontaneous involution. The 
proliferative phase spreads over three to six months. Most Infantile 
hemangiomas do not require therapy and regress spontaneously 
over months to years. However, about 10-15% of the cases result in 
complications such as obstruction, ulceration and disfigurement. It 
may also carry risk of bleeding. Treatment is required in such 
conditions [1]. Therapeutic effect of Propranolol over Infantile 
hemangioma was detected incidentally in the year 2008, when 
regression of facial hemangioma was noted in a child while being 
treated for hypertrophic cardiomyopathy by this molecule [5]. Since 
then, it is being used for infantile hemangioma and currently oral 
Propranolol is the treatment of choice for this condition [6]. 
However, there is lack of consensus over its dosage as cited in 
literature of different studies [7-9]. 
 
Propranolol has been used for cardiovascular indications in the 
dosage up to 4mg/kg/d, but for treatment of infantile hemangioma, 
a lower dose is required. For treatment of Infantile hemangioma, 
some studies favor a lower dose (1-1.5 mg/kg/dose) [7, 8], while 
others favor a higher dose (3mg/kg/day) [9]. The precise 
mechanism of action of Propranolol in the treatment of infantile 
hemangioma is unclear. The possible mechanisms include 
vasoconstriction, inhibition of angiogenesis and induction of 
apoptosis [6]. Although Propranolol has been widely used for this 
indication, other Beta blockers like Nadolol [10-13] and Acebutolol 
[14] have also been shown to be effective for Infantile hemangioma 
in small non-controlled studies. Other agents with reported activity 
in treating Infantile hemangioma include corticosteroids, Interferon 
alpha and Vinca alkaloids [15]. Besides pharmacotherapy, other 
treatment modalities include Laser therapy and surgical resection. 
Sometimes a combination of these modalities is required [16]. We 
conducted a prospective cross sectional study in 25 cases of 
infantile hemangioma to find out appropriate dosage of oral 






Twenty seven patients of age 2 months and older, with vascular 
lesions suggestive of infantile hemangioma on clinical grounds, were 
selected. Approval from ethics committee of the institute was taken. 
History of any hypoglycemic event with the child was enquired. 
History of any heart block in the mother was also enquired in view 
of its potential association with complete heart block in the child. 
Baseline heart rate & blood pressure were noted. ECG and 
echocardiography were done to rule out any conduction or 
structural abnormality. Ultrasonography of the vascular lesions was 
done to confirm the diagnosis of infantile hemangioma. Abdominal 
ultrasound was also done to look for any hemangioma inside the 
abdomen. One patient was lost to follow up during initial 
investigations. Lesion of another patient came out to be venous 
malformation on ultrasonography, hence excluded. Amongst the 
remaining 25 patients, there were 18 males and 7 females. It was 
planned to start oral propranolol in patients with treatment 
indications, at the dose of 1 mg/kg/day with gradual increment by 
0.5 mg/kg/d in subsequent visits. Daily dose of this medicine was 
given in two divided doses. First follow up was planned after 1 
week, thereafter every 2 week till any response was observed or full 
dose of 3-4 mg/kg/d was reached. Indications for starting 
propranolol therapy were functional impairment, risk of bleeding 
and aesthetic concerns. Lower respiratory tract infection related 
bronchospasm was noted in two infants and they were treated 
before starting propranolol. Exclusion criteria were previous 
treatment with propranolol, rhythm abnormality like complete heart 
block, ventricular systolic dysfunction and any structural cardiac 
abnormality like ASD/VSD or PDA. 25 patients were selected for 
starting oral propranolol therapy, based on the above indications. 24 
patients were given oral propranolol with starting dose of 1 
mg/kg/d, as OPD treatment. 
  
One patient aged 2 months was admitted for 1 day for beginning 
oral propranolol and observation of any side effects. Caregivers of 
the child were advised to ensure regular feeding of the child to 
avoid hypoglycemia and to report back anytime in case of any 
adverse event, possibilities of which were explained to them. On 
follow up visit, response to the treatment was evaluated. Any fading 
of color of the tumor based on comparison with the previous 
photograph (in case of superficial hemangioma) or any decrease in 
size of the lesion were assessed. Blood pressure and heart rate 
were checked to look for any side effects like hypotension and 
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bradycardia. Patients who tolerated the propranolol well, were given 
increased dose, 1.5 mg/kg/day after one week. Two patients with 
superficial hemangioma were noted to have marked response on 
follow up after 1 week in the form of marked fading of the color of 
hemangioma and reduction in its size and it was decided to continue 
with the same dose of 1 mg/kg/day in them for further duration of 
therapy. 2 infants developed irritability within 1 week of starting 
therapy and propranolol was discontinued in them. Others were 
treated as per plan. Those who responded to therapy with fading of 
color of tumor as compared to previous photograph, softening in 
consistency of the tumor or reduction in its size on physical 
measurement, were continued on same dose and a monthly follow 
up was done subsequently. Response for the deep (subcutaneous) 
hemangioma was assessed by physical measurement of the tumor. 
For this study, response was defined as 'subsided' when there was 
≥ 90% reduction in size of tumor and 'partial' when reduction in 
tumor size was < 90%. Lei chang et al. used the similar parameter 
of measurement for labeling hemangioma as 'regression' and 'partial 
regression' after propranolol therapy [17]. In non-responders, the 
dose of propranolol was gradually increased at the rate of 
0.5mg/kg/d every month till any response was observed or the 
maximum dose of 3-4mg/kg/dose was achieved. If no response was 
noted, one month after the maximum dose, propranolol was 
discontinued in them. In responder group, the criteria for tapering 
off propranolol was decided on the basis of subsidence of the 
tumor, decrease in tumor size and keeping the same size for 3 
consecutive months and the child has received a minimum of 6 
months of therapy. Follow up was done for 6 months after 





25 patients were started on oral Propranolol for treatment of their 
Infantile hemangioma. There were 18 males and 7 females (Table 
1). Head and neck region was predominantly involved (76%) with 
infantile hemangioma (Figure 1). Two infants developed irritability 
during first week of therapy and lost to follow up. 1 patient lost to 
follow up after 1 month of treatment. 22 patients were further 
continued with the treatment. 17/22 (77%) patients responded to 
the treatment with regression of the tumor size (Figure 2, Figure 
3, Figure 4, Figure 5, Figure 6). Median dose of Propranolol in the 
responder group was 1.5 mg/kg/day. 1/22(5%) patient showed 
partial response. Response rate was maximum 93% (15/16) in 
children of ≤ 1 year age group (Table 2). 5/22(24%) patients did 
not respond to the treatment (Figure 2). Response to treatment in 
superficial hemangioma in the form of color change was noted 
within 1 week of starting therapy. Average duration of therapy was 
10 months. 5 patients, who did not respond to the lower dose, were 
given gradually escalated dose of 3-4 mg/kg/day (4 patients 
received 3mg/kg/d & 1 Patient received 4 mg/kg/day). They were 
evaluated after 1 month after starting this maximum dose and when 
no response was observed in them, they were discontinued 
Propranolol therapy. None of the 22 patients (even one who was 
given 4mg/kg/d of Propranolol), were found to have bradycardia. 
5/13 cases of superficial hemangioma developed ulceration during 
therapy and they were managed with topical Mupirocin. Two 
patients had an unusual side effect of itching over lesion after 
beginning of oral Propranolol. They were managed with two weeks 
of oral Hydroxyzine. Besides irritability in two infants and local 
ulceration over the lesion in 4 children, no significant side effects 
were noticed (Table 3). Follow up was done for 6 months after 
completion of therapy. 2/21 (10%) patients showed recurrence of 
lesion after completion of therapy. They were 10 months and 11 
months old after completion of 6 months and 9 months of therapy 
respectively. They responded with further extending the duration of 






After the incidental discovery of therapeutic effect of oral 
propranolol in treatment of infantile hemangioma, it has become the 
treatment of choice [18]. Most of the superficial hemangioma 
responded to the lower dose of propranolol (1.5mg/kg/dose) and 
those who responded, showed response within one week of starting 
treatment. Maximum response was noted in infants (< 1 year age 
group). Ren W et al (2017) also described effectiveness of low dose 
propranolol (1-1.5mg/kg/day) with change in color and growth of 
the tumor within one week [7]. Gabor Katona et al (2012) described 
resembling findings of the effect of propranolol used in the dosage 
of 2mg/kg/day, as regression in tumor size in first week [19]. After 
initial regression, the later improvement is much slower, sometimes 
with periods of stagnation. The treatment should be continued for 
at least 6 months because early cessation can cause a relapse [19]. 
Cessation of therapy before 1 year of age also may be associated 
with a relapse [20, 21]. 
Page number not for citation purposes 4 
  
Ultrasonography is a good tool for objective assessment of the 
change in tumor size [22]. Leaute-Labreze et al.conducted a 
controlled trial with 1mg/kg/d and 3 mg/kg/d of oral propranolol 
with approximately 100 patient in each group. They found complete 
or near complete resolution of the hemangioma after six months of 
oral propranolol in 50% of the patients in 1 mg/kg/d group as 
compared to 60% in 3 mg/kg/day group, but the side effects like 
hypotension was more common in 3mg/kg group (3% vs 1%). 
Similarly Bronchospasm was more common in 3 mg/kg group 
compared to 1 mg/kg group (1% vs 0%) [23]. They observed that 
agitation as a side effect is more common in 1 mg/kg group (18%) 
as compared to 3 mg/kg(8%) group. This means that this side 
effect of propranolol is dose independent. We also observed 
irritability in 8% of children after starting propranolol therapy. This 
is important to explain to the caregiver of the child regarding 
possible side effects of propranolol before starting treatment. Lei 
Chang et al. described that there is individual variation of response 
after administration of propranolol. Chinese subjects have at least 
two fold greater sensitivity to propranolol [17]. We also suggest that 
the dose of propranolol should be individualized. A lower dose 
should be considered for therapy, if the response is observed with 
the lower dose. The non-responders who were labeled to have 
hemangioma on the basis clinical grounds and ultrasonography, 
might have had anatomically or histologically different lesion. We 
have found recurrence in 2 infants when the propranolol therapy 
was tapered off before 1 year of age. Thus the possibility of 
recurrence should be a point of consideration while tapering off 
propranolol therapy. 
  
Recommendations: for the treatment of infantile hemangioma, dose 
of propranolol should be individualized and started with a lower 
dose with gradual escalation. If response is achieved with the lower 
dose (1-1.5 mg/kg/dose), further treatment should be continued 
with the lower dose. Those who show a marked response after 
initiation of therapy at the dose of 1 mg/kg/day, should be 
continued with the same dose till regression of the tumor size. If 
response is not achieved 1 month after the maximum dose (3-
4mg/kg/day), it is unlikely that infantile hemangioma will respond to 
this pharmacotherapy and it should be discontinued to consider 
other modalities of treatment. Most of the patients can be managed 
as outpatient. Parents should be explained regarding possible side 
effects of propranolol including hypoglycemia and should be advised 
that the child needs to be fed regularly. They should also be 
explained that in case of any adverse event, they should discontinue 
propranolol and take medical consultation in nearby health facility. 
Inpatient management has been advocated for infants and children 
with - corrected gestational age of ≤ 8weeks, inadequate social 
support, comorbid conditions affecting the cardiovascular system, 
symptomatic airway hemangioma and history of hypoglycemia. As 
recurrence is more common if propranolol is stopped before 6 
months of treatment or before 1 year of age of the child, it is logical 






Oral propranolol in the lower dose of 1-1.5 mg/kg/day is safe and 
efficacious in treatment of infantile hemangioma. Those who do not 
show initial response to the lower dose, remain unresponsive even 
at higher dose of 3-4 mg/kg/day. Most of the children can be 
treated as outpatient after proper counselling regarding possible 
side effects of propranolol. 
  
Limitations of the study: Although we suggest individualized and 
lower dose of propranolol therapy as per findings of this study, the 
limitations of this study are that this is an open labeled study and 
sample size is small. 
 
What is known about this topic 
 Oral propranolol is efficacious in treatment of infantile 
hemangioma; 
 Low dose propranolol (1-2 mg/kg/day) as well as higher 
dose propranolol (3mg/kg/d) has been used to treat this 
condition; 
 Recurrence of hemangioma after the treatment is a 
known complication if propranolol is stopped before 1 
year of age. 
What this study adds 
 Dose of oral propranolol in treatment of infantile 
hemangioma should be individualized. Treatment should 
be started with the low dose (1-1.5 mg/kg/d) and if the 
response is observed on a low dose, the same may be 
continued for further course of therapy. It is advisable to 
continue this pharmacotherapy beyond 1 year of the age 
to avoid recurrence. 
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 Infantile hemangioma which does not show initial 
response to the lower dose (1-1.5mg/kg/day) of 
propranolol is unlikely to respond to its higher dose (3-4 
mg/kg/d). Older children are less likely to respond with 
oral propranolol therapy for their infantile hemangioma. 
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Table 1: Age and sex distribution of infantile hemangioma (n=25) 
Age group Male Female Total (%) 
≤1 year 13 5 18(71%) 
>1 year- 5 Year 4 1 5 (19%) 
>5 years 1 1 2 (9%) 




Table 2: Response to propranolol therapy in different age group (n=22) 
Age Group Total No. Response No Response 
≤1year 16 15 1 
>1Year -5 Year 4 2 2 




Table 3: Side effects of propranolol therapy (n=25) 
Side effects Number (%) 
None 17 (68) 
Ulceration over lesion 05 (20) 
Irritability 02 (08) 
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Figure 2: Effect of propranolol therapy on infantile hemangioma 
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Figure 6: Hemangioma of lip unresponsive to propranolol therapy 
 
